Table 4.
Association of serum fibroblast growth factor-23 with cardiovascular events, heart failure events, and mortality in SPRINT participants with CKD
| Outcome | FGF23 Q1 | FGF23 Q2 | FGF23 Q3 | FGF23 Q4 | Per 2-Fold Higher FGF23 | P Value |
|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | ||
| Range, pg/ml | 12.7–51.9 | 52.0–66.4 | 66.5–87.6 | 87.7–1687 | ||
| Cardiovascular events, n (%) | 54 (9) | 66 (11) | 65 (11) | 75 (13) | 261 (11) | |
| Model 1 | Reference | 1.21 (0.83 to 1.76) | 1.22 (0.84 to 1.78) | 1.49 (1.04 to 2.14) | 1.26 (1.04 to 1.52) | 0.02 |
| Model 2 | Reference | 1.11 (0.76 to 1.63) | 0.96 (0.65 to 1.43) | 0.97 (0.64 to 1.48) | 0.99 (0.78 to 1.24) | 0.91 |
| Heart failure, n (%) | 18 (3) | 18 (3) | 34 (6) | 32 (5) | 102 (4) | |
| Model 1 | Reference | 1.07 (0.54 to 2.13) | 1.90 (1.05 to 3.56) | 1.85 (1.02 to 3.46) | 1.37 (1.03 to 1.79) | 0.03 |
| Model 2 | Reference | 0.93 (0.46 to 1.88) | 1.25 (0.66 to 2.41) | 0.88 (0.43 to 1.80) | 0.93 (0.63 to 1.34) | 0.71 |
| All-cause mortality, n (%) | 48 (8) | 31 (5) | 37 (6) | 63 (11) | 179 (5) | |
| Model 1 | Reference | 0.62 (0.39 to 0.99) | 0.82 (0.53. 1.28) | 1.28 (0.87 to 1.90) | 1.23 (0.98 to 1.53) | 0.08 |
| Model 2 | Reference | 0.57 (0.35 to 0.92) | 0.61 (0.38 to 0.97) | 0.70 (0.44 to 1.11) | 0.80 (0.60 to 1.06) | 0.13 |
Model 1: adjusted for age, sex, race, and randomized treatment arm. Model 2: adjusted for model 1 variables plus eGFR (using creatinine and cystatin C), urine albumin-to-creatinine ratio, prevalent cardiovascular disease, prevalent heart failure, systolic BP, number of antihypertensives at baseline, smoking, body mass index, total cholesterol, and HDL cholesterol. SPRINT, Systolic Blood Pressure Intervention Trial; FGF23, fibroblast growth factor-23; Q, quartile; HR, hazard ratio; 95% CI, 95% confidence interval.